Journal of Pediatric Neurology
DOI: 10.1055/s-0040-1721380
Case Report

Dexmedetomidine Infusion as a Novel Supportive Therapy for Fluphenazine-Induced Neuroleptic Malignant Syndrome in a 10-Year-Old Boy: A Case Report and Review of Literature

Caroline Yu
1  Department of Pediatrics, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States
,
Rajat Kaul
2  Division of Pediatric Hospitalist Medicine, Department of Pediatrics, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States
,
Waseem Ostwani
3  Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States
› Author Affiliations
Funding None.

Abstract

A 10-year-old boy developed symptoms of neuroleptic malignant syndrome (NMS) 1 month following initiation of fluphenazine for behavioral therapeutic management. Dexmedetomidine infusion was able to adequately control the symptoms of NMS with resolution of encephalopathy. This is the first report of novel dexmedetomidine utilization for the treatment of NMS. We suggest using dexmedetomidine as an adjunctive agent to control NMS symptomatology without attendant risk of respiratory depression.



Publication History

Received: 03 October 2020

Accepted: 21 October 2020

Publication Date:
18 December 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany